ADC Therapeutics Awards $4.2M in Retention Bonuses and RSUs to Top Executives Amidst Restructuring
ADCT sits 54% above its 52-week low of $0.78.
Summary
ADC Therapeutics is granting over $4.2 million in cash and RSUs to its top executives as retention awards, following a major clinical setback and company restructuring.
Key Events · Executive and Board Changes · ADCT
-
CEO Awarded $1.79M Cash and 675K RSUs
CEO Ameet Mallik received a cash incentive award of $1,795,500 and 675,000 Restricted Stock Units (RSUs).
-
CFO Awarded $541.8K Cash and 203.7K RSUs
CFO Jose Carmona received a cash incentive award of $541,842 and 203,700 RSUs.
-
CMO Awarded $568.9K Cash and 213.9K RSUs
CMO Mohamed Zaki received a cash incentive award of $568,974 and 213,900 RSUs.
-
Total Executive Awards Valued at $4.22M
The total value of these one-time retention awards, including cash and RSUs (valued at current stock price), is approximately $4.22 million.
Analysis · ADCT · Life Sciences
ADC Therapeutics has approved substantial one-time retention awards totaling over $4.2 million in cash and restricted stock units (RSUs) for its CEO, CFO, and CMO. This significant compensation package, representing nearly 3% of the company's market capitalization, comes shortly after a major clinical trial failure, a sharp decline in stock price, and a workforce reduction. While intended to retain key leadership during a critical period of restructuring and strategic refocusing, the substantial cost and dilution are likely to be viewed negatively by existing shareholders.
At the time of this filing, ADCT was trading at $1.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $151.4M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.